Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Key Points • Pola-DA-EPCH-R has an acceptable safety profile that is similar to that of previously published results of the standard DA-EPOCH-R regimen.• Substituting vincristine with Pola did not appear to affect the ability to escalate chemotherapy dosing beyond dose level 1.

[1]  P. Riedell,et al.  Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial , 2022, Nature Medicine.

[2]  R. Greil,et al.  Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[3]  J. Friedberg,et al.  Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701 , 2021, Blood.

[4]  J. Leonard,et al.  Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. , 2021, The Lancet. Haematology.

[5]  Ash A. Alizadeh,et al.  Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA , 2021, Nature Biotechnology.

[6]  R. Gascoyne,et al.  ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Sehn,et al.  Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Staudt,et al.  Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Staudt,et al.  Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Wilson,et al.  Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. , 2018, The Lancet. Haematology.

[11]  Ash A. Alizadeh,et al.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Leonard,et al.  Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Burke,et al.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Manish R. Patel,et al.  Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. , 2015, The Lancet. Oncology.

[15]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Elaine S. Jaffe,et al.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. , 2013, The New England journal of medicine.

[17]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[18]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[19]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[20]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.